{"nctId":"NCT02603120","briefTitle":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","startDateStruct":{"date":"2015-11-11","type":"ACTUAL"},"conditions":["HIV-1 Infection"],"count":567,"armGroups":[{"label":"Blinded Phase: B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF","Drug: ABC/DTG/3TC Placebo"]},{"label":"Blinded Phase: ABC/DTG/3TC","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABC/DTG/3TC","Drug: B/F/TAF Placebo"]},{"label":"Open-Label Phase","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]}],"interventions":[{"name":"ABC/DTG/3TC","otherNames":["Triumeq®"]},{"name":"B/F/TAF","otherNames":["Bictegravir (previously referred to as GS-9883)/Emtricitabine/Tenofovir Alafenamide","Biktarvy® [BVY]"]},{"name":"ABC/DTG/3TC Placebo","otherNames":[]},{"name":"B/F/TAF Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec).\n* Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for ≥ 3 months prior to the screening visit.\n* HIV ribonucleic acid (RNA) \\< 50 copies/mL at the screening visit.\n* Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented plasma HIV-1 RNA \\< 50 copies/mL for ≥ 3 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).\n* Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), DTG, ABC or 3TC.\n\nKey Exclusion Criteria:\n\n* Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance.\n* Active tuberculosis infection.\n* Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).\n* Females who are pregnant.\n* Females who are breastfeeding.\n* Acute hepatitis in the 30 days prior to study entry.\n* Chronic Hepatitis B Virus (HBV) infection.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31","spread":"181.3"},{"groupId":"OG001","value":"4","spread":"191.0"}]}]}]},{"type":"SECONDARY","title":"Spine Bone Mineral Density (BMD) at Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.124","spread":"0.1833"},{"groupId":"OG001","value":"1.103","spread":"0.1548"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Spine BMD at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.692","spread":"3.1296"},{"groupId":"OG001","value":"0.416","spread":"2.9973"}]}]}]},{"type":"SECONDARY","title":"Hip Bone Mineral Density at Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.006","spread":"0.1471"},{"groupId":"OG001","value":"0.996","spread":"0.1363"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hip BMD at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.156","spread":"2.2138"},{"groupId":"OG001","value":"0.299","spread":"2.1077"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":282},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Headache","Arthralgia"]}}}